14α-Hydroxypaspalinine
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Category | Others |
Catalog number | BBF-04735 |
CAS | 151341-77-4 |
Molecular Weight | 449.54 |
Molecular Formula | C27H31NO5 |
Purity | >95% by HPLC |
Online Inquiry
Capabilities & Facilities
Fermentation Lab
4 R&D and scale-up labs
2 Preparative purification labs
Fermentation Plant
Semi pilot, pilot and industrial plant 4 Manufacturing sites 7 Production lines at pilot scale 100+ Reactors of 30-4000 L; 170+ reactors of 20 KL-30 KL; 24+ reactors of >100 KL 2 Hydrogenation reactors (200 L, 4Mpa and 1000L, 4Mpa)
Product Description
14α-Hydroxypaspalinine is a secondary metabolite of indole isolated from Aspergillus niger. 14-α-hydroxypaspalinine is a member of the paspalinine-causing toxin family and is usually related to the toxicity of animals to pasture.
- Specification
- Properties
- Reference Reading
- Price Product List
Synonyms | Hydroxypaspalinine, 14-alpha- |
Storage | Store at -20°C |
IUPAC Name | (1S,4R,5S,16R,18S,19S,23R)-18,19-dihydroxy-4,5,24,24-tetramethyl-25,26-dioxa-7-azaheptacyclo[21.2.1.01,20.04,19.05,16.06,14.08,13]hexacosa-6(14),8,10,12,20-pentaen-22-one |
Canonical SMILES | CC1(C2C(=O)C=C3C(O2)(O1)CCC4(C3(C(CC5C4(C6=C(C5)C7=CC=CC=C7N6)C)O)O)C)C |
InChI | InChI=1S/C27H31NO5/c1-23(2)22-18(29)13-19-26(32-22,33-23)10-9-24(3)25(4)14(12-20(30)27(19,24)31)11-16-15-7-5-6-8-17(15)28-21(16)25/h5-8,13-14,20,22,28,30-31H,9-12H2,1-4H3/t14-,20+,22+,24-,25-,26+,27+/m1/s1 |
InChI Key | JNHPMJVSUJKCKH-KCCNSQSLSA-N |
Solubility | Soluble in ethanol, methanol, DMF, DMSO |
BBF-02800 | DB-2073 | Inquiry |
BBF-03774 | Cephalosporin C Zinc Salt | Inquiry |
BBF-05817 | Astaxanthin | Inquiry |
BBF-03904 | Nosiheptide | Inquiry |
BBF-02575 | Pneumocandin A0 | Inquiry |
BBF-03862 | Cefozopran hydrochloride | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
